Which Factors Will Push The Inflammatory Bowel Disease Treatment Market To Achieve $39.39 Billion By 2029?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Is The Predicted Market Size Of The Inflammatory Bowel Disease Treatment Industry By 2029?
The market size for inflammatory bowel disease treatment has seen robust growth over recent periods. It is set to expand from a value of $25.26 billion in 2024 to $27.19 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.6%. Factors such as the rising incidence of inflammatory bowel disease, the higher demand for biologics and immunomodulators, enhanced treatment methods, an increasing elderly population, and heightened disease awareness have contributed to the growth in the previous periods.
The market size for treatment of inflammatory bowel disease is projected to experience robust expansion in the years ahead, reaching “$39.39 billion by 2029” with a compound annual growth rate (CAGR) of 9.7%. This anticipated increase during the forecast period is due to escalating investment in R&D endeavors, surging demand for biosimilars, a rising number of inflammatory bowel disease incidences in evolving markets, enhanced demand for bespoke medication, and the incorporation of precision medicine into IBD treatment strategies. Noteworthy trends predicted for the forecasting period encompass a mounting number of product debuts and approvals, customized dosage and management plans for IBD, the employment of telemedicine for distant IBD patient monitoring, research into microbiome-related therapies for IBD, and the acceptance of value-oriented care models in IBD therapy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
Which Industry Forces Are Driving The Inflammatory Bowel Disease Treatment Market Forward?
The increase in cases of Crohn’s disease and ulcerative colitis is a key factor propelling the growth of the inflammatory bowel disease treatment market. These conditions, known as types of inflammatory bowel diseases (IBD), lead to the inflammation and creation of ulcers (sores) in the digestive tracts. The escalating incidences of Crohn’s disease and ulcerative colitis will likely spur the demand for inflammatory bowel disease treatments, which are predominantly used to minimize bowel inflammation and fend off medical complications. For example, research published in the United States National Library of Medicine in March 2022, a medical library based in the US, indicates that approximately 1.6 million Americans are currently battling inflammatory bowel disease (either Crohn’s disease or ulcerative colitis), and around 70,000 new IBD cases are identified annually in the USA. Thus, the growing number of Crohn’s disease and ulcerative colitis cases is anticipated to stimulate the expansion of the inflammatory bowel disease treatment market.
What Is The Segment Breakdown Of The Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
How Are Global Trends Impacting The Development Of The Inflammatory Bowel Disease Treatment Market?
The trend of technological progression is emerging prominently in the market for inflammatory bowel disease therapy. Many leading enterprises in the inflammatory bowel disease treatment landscape are adopting strategies that utilize AI-based registries to stand out in the competitive environment. Verantos, a company providing real-world evidence (RWE) based in California, exemplified this in May 2024 by launching the Inflammatory Bowel Disease Pragmatic Registry. This initiative leverages state-of-the-art artificial intelligence to produce reliable, real-world evidence for managing Ulcerative Colitis and Crohn’s disease. The purpose of the register is to support the creation of efficacious therapeutic methods by delivering a comprehensive data set exceeding 3 billion data points that inform patient care. It offers biopharmaceutical investigators in-depth knowledge pertaining to disease severity, the efficacy of treatments, and clinical results using both structured and unstructured data obtained from electronic health records.
Which Companies Are Contributing Significantly To The Inflammatory Bowel Disease Treatment Market Growth?
Major companies operating in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic – Gastroenterology West P. C., Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.
Access The Complete Report Here:
Which Region Is Leading Innovation In The Inflammatory Bowel Disease Treatment Market?
North America was the largest region in the inflammatory bowel disease treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
